Shares of Monogram Technologies (MGRM) surged 100% in early trading following the announcement of a definitive agreement to be acquired by Zimmer Biomet (ZBH) in a deal that aims to reshape the future of orthopedic surgery. Under the terms of the agreement, Zimmer Biomet will purchase all outstanding shares of Monogram for $4.04 per share in cash. The agreement values the company at approximately $177 million in equity and $168 million in enterprise value. In addition to the upfront payment, Monogram shareholders will receive a contingent value right (CVR) worth up to $12.37 per share, payable if a series of product development, regulatory, and revenue milestones are achieved through 2030.
Monogram's robotics platform, including its AI-driven, semi-autonomous knee arthroplasty technology, was cleared by the FDA in March 2025 and is scheduled for commercialization using Zimmer Biomet implants in early 2027. A fully autonomous version is also under development. Once the deal closes, Zimmer Biomet is expected to be the first company in the orthopedic space to offer a fully autonomous surgical robot. The move will integrate Monogram's proprietary CT-based system into Zimmer's existing ROSA robotics platform.
The acquisition is expected to contribute to Zimmer Biomet's revenue growth beginning in 2027, with earnings accretion projected from 2028 onward. Monogram's board has unanimously approved the deal, and Zimmer Biomet plans to finance the transaction using a combination of balance sheet cash and available debt resources. Closing is anticipated later this year, subject to shareholder and regulatory approvals.
Shares of MGRM surged 100% in early trading on the announcement.
The post Monogram Technologies to Be Acquired by Zimmer Biomet in Transformational Robotics Deal appeared first on PRISM MarketView.
COMTEX_467324132/2927/2025-07-14T12:01:42